Search results for ""Author Manzoor Ahmad Mir""
Elsevier Science & Technology Human Pathogenic Microbes: Diseases and Concerns
Considering the global emerging human pathogenic microbial diseases and trends, Human Pathogenic Microbes is framed to provide deep insights into the epidemic and emerging bacterial and fungal infections and diseases in humans. It presents novel, up-to-date, and cutting-edge knowledge regarding various human pathogenic microbes, their associated drug resistance mechanisms, and different diseases caused by them. Human Pathogenic Microbes reflects the current research and development on the evolution of bacterial and fungal drug resistance: different bacterial and fungal antimicrobial drug resistance mechanisms along with their biological and molecular aspects. In a nutshell, Human Pathogenic Microbes describes a various bacterial and fungal diseases caused by different human pathogenic microbes employing different drug resistance mechanisms and processes. It also highlights the novel emerging approaches (Immunological and combinatorial) that will aid to fight against such bacterial and fungal pathogens.
£121.50
Elsevier Science & Technology Combinational Therapy in Triple Negative Breast Cancer
Combinational Therapy in Triple Negative Breast Cancer discusses TNBC at the molecular level from a holistic approach, focusing on combinational strategies targeting various pathways involved in this specific cancer type. Using a monotherapy for the treatment of cancer, especially high-grade tumors like TNBC, is mostly worthless due to the inherent genetic instability of tumor cells to develop intrinsic and acquired resistance. Combination therapy presents more, or at least the same, effectiveness with lower doses of every single agent and decreases the likelihood of chemoresistance, making it essential to understand for multiple therapy options. The book is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of combinational therapies to treat triple negative breast cancer.
£114.30